Henlius stands out in Hong Kong’s cooling biotech market with profits and pipeline progress
In recent months, as Hong Kong’s biotech and innovative drug market has cooled, even major business development deals have failed to energize investors. Market attention has returned to what truly drives long-term value for pharmaceutical companies: …